4.2 Article

Progressive multifocal leukoencephalopathy in multiple myeloma

Related references

Note: Only part of the references are listed.
Article Medicine, General & Internal

Teclistamab in Relapsed or Refractory Multiple Myeloma

Philippe Moreau et al.

Summary: Teclistamab demonstrated promising efficacy in patients with relapsed or refractory multiple myeloma, leading to high rates of deep and durable response. Common adverse events included cytokine release syndrome, cytopenias, and infections, with toxic effects mostly grade 1 or 2.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Article Medicine, General & Internal

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Nikhil C. Munshi et al.

Summary: The phase 2 study confirmed the efficacy and safety of ide-cel in patients with relapsed and refractory myeloma, with a majority of patients achieving responses and 26% achieving MRD-negative status. Despite the high response rate, almost all patients experienced grade 3 or 4 toxic effects, including hematologic toxic effects and cytokine release syndrome.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Medicine, General & Internal

Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy

Irene Cortese et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Article Clinical Neurology

Progressive multifocal leukoencephalopathy A 25-year retrospective cohort study

Pria Anand et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2019)

Meeting Abstract Oncology

Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Myeloma

Yildiz Aydin et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)

Review Clinical Neurology

Progressive Multifocal Leukoencephalopathy: Current Insights

Marge Kartau et al.

DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE (2019)

Letter Oncology

Lenalidomide-associated progressive multifocal leukoencephalopathy

Francesco Brigo et al.

LEUKEMIA & LYMPHOMA (2017)